• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Aphena Pharma Solutions

    Reed-Lane

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Cytovance Biologics

    Alcami

    Emergent BioSolutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism

    The rise of new tools and approaches, an increase in regulatory responsibility, and the need for speed.

    COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism
    Related CONTENT
    • Lonza Capsules and Health Ingredients
    • Eurofins Viracor Biopharma Services
    • MedPharm
    • Batavia Biosciences
    • PPD Achieves ISO Information Security Management Certification
    Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances05.18.20
    Amid the COVID-19 pandemic, it’s not easy to think about next year. The pharmaceutical industry is leading the charge to find therapies and develop vaccines, while simultaneously modifying existing trials to the new environment, and keeping their staff and patients safe. But the industry will be different after the crisis passes, and sponsors must prepare for it.

    Some of those differences are already becoming clear. Few scientists doubt that the novel coronavirus will be the last to emerge. There will be more generous incentives for companies to invest in developing vaccines and infectious disease (ID) drugs. The public and policymakers will push for the accelerated development of new and affordable medicines, as the pandemic has shined a bright light on disturbing healthcare inequities. Accelerated development will demand more real-world evidence (RWE) – with concomitant greater transparency in industry-regulatory communications and relations – as well as adaptive and hybrid trials to make activities in all stages of development more parallel and less sequential. At the same time, trials will become more decentralized and patient-centric to increase convenience for enrollees.

    There is a theme emerging in all these changes: a new pragmatism. The sooner companies can adapt, accelerate change, and plan for tomorrow’s challenges, the stronger their positions will be. And the better prepared they will be to continue creating and marketing new drugs for patients who need them.

    What the new pragmatism will mean
    In our daily lives, whatever we can do remotely, we’re now doing. In many instances, we’re discovering it is more efficient. The same will be true in drug development. Whatever can be done remotely, will be, and that may prove to be for the better.

    Clinical trials: The rise of new tools and approaches
    Due to limited (or no) access to clinical sites, many trials have been put on hold. But for many others, including some of those run by Parexel, sponsors and managers are transitioning to distributed trials with remote monitoring and source document verification (SDV) to ensure that participating patients can continue to benefit.

    While COVID-19 occupies the world’s attention, there are still substantial public health challenges in oncology, heart disease, and many other major and rare conditions. Clinical research must continue. For it to do so, sponsors and CROs must maximize their creativity while staying aligned with regulators. Drawing on our experience in late-phase studies, Parexel has have implemented technologies and approaches— such as eConsent, wearables, telehealth, telemedicine, and remote SDV – for remote monitoring of Phase II and III studies.

    For example, telemedicine was not widely reimbursed by many insurers, including Medicare, before the pandemic. Now it is, and that will likely continue. The limitations that slowed the adoption of mobile technologies in clinical trials, including concerns about excluding bad or missing data, user errors, and the lack of device validation, will fade as the incentive to overcome them becomes compelling. The feeling that these tools would be “nice to have someday” has become “we need it today.”

    We are unlikely to return to the old ways of conducting clinical trials once we have discovered the benefits of these new tools for researchers, patients, and regulators. And sponsors that become adept at using them will prosper in the future.

    Regulatory: An increase in responsibility
    The lives of regulators have changed dramatically, as most now have to work from home. Meetings that once took place in person – EMA scientific consultations, FDA end-of-Phase 2 meetings, even FDA Advisory Committee meetings – are now being held remotely if they’re being held at all. Sponsors must think pragmatically and learn to live with this new reality, even if it’s less desirable, and make the most of their available interactions with regulators.

    In the last six weeks, 50 of the world’s regulatory agencies have issued new guidance on how sponsors should manage ongoing clinical trials and launch new ones. This guidance illustrates new flexibility regarding clinical trial management. However, standards on GCP compliance have not been lowered, and all amendments, protocol deviations, and adverse events must be reported diligently. Regulations are critical to safe drug development; loosening them can put patients in harm’s way.

    Regulators are allowing sponsors greater independence in how they maintain compliance during this emergency. But sponsors should still maintain GMP and GCP compliance as tightly as possible to protect their development plans, ensure ultimate regulatory approval, and preserve the lifecycle of their products on the market. They have to balance creativity in conducting and managing compliant clinical trials with the expectation that they will have to satisfy regulators’ expectations. Importantly, ICMRA and its 29-member agencies have called for the conduct of large, well-designed, and controlled clinical trials to address COVID-19. To answer this call, sponsors must push the envelope of pragmatism by setting aside their differences and collaborating for the common good.

    Once sponsors and CROs master this new regulatory environment – which has the potential to create new efficiencies, shorten response times, and reduce costs – there will be little incentive – scientific, operational, or financial – to return to old ways of operating. That genie is out of the bottle.

    GMP enforcement: Remote rigor
    Today, manufacturing plants around the world in receipt of regulatory enforcement letters are trying to retool and remediate their operations to get back into compliance quickly and cost-effectively, calling on experts for help. But those experts cannot now travel to sites in India, South Korea and China, and who knows when they will be able to? International auditing guidelines allow for remote auditing; regulatory authorities are issuing guidance to better facilitate them during the pandemic; and experts and starting to direct and monitor remediation efforts remotely, using video, virtual reality, and other advanced tools.

    In the future, we can expect that experts will spend less time on planes, less time navigating new environments, and more time working on problems. This will be better for patients, manufacturers, supply chain managers and regulators, and more cost-effective for everyone, including payers.

    Major regulators have largely discontinued manufacturing plant inspections for the time being, or do what they can do remotely. But they have not lowered their expectations that plants must be GMP-compliant. Indeed, it’s not unreasonable to expect more scrutiny as supply chain disruptions increase the risk of GMP deviations. This is no time for manufacturers to relax their GMP focus and discipline.

    Where investments will move
    For many years now, funding for R&D in infectious disease treatments or vaccines has come mainly from government entities, such as the U.S. National Institute of Allergy and Infectious Diseases, and philanthropic organizations, including the Bill & Melinda Gates Foundation. The biopharma industry has invested its development dollars in other areas, and infectious disease programs currently represent less than 2 percent of the overall development pipeline. The COVID-19 pandemic has revealed the enormous danger (and cost) of not having vaccines to hand, and society may be ready to spend more on reimbursing and rewarding good drugs and vaccines to avoid future human and economic catastrophes. The almost incalculable GDP impact of the pandemic, and the value of prevention, are now visible to even the most conservative policymakers and governments. Hence interest and investment in these areas by the industry will likely increase.

    To spur greater investment in infectious disease, policymakers will need to address both “push” and “pull” incentives. While funding grants (push) and regulatory incentives can help companies de-risk the early stages of development, they do not address the low return on investment. This low ROI is driven by the entrenched use of generics and by antibiotic stewardship by providers, who reserve novel antibiotics to mitigate resistance, resulting in infrequent prescribing and poor brand usage.  Pull incentives would create more certain and attractive returns for successful antibiotic development.

    These could include market-entry rewards, such as payments over multiple years to companies after approval or transferable vouchers that would extend the exclusivity period on other drugs in a company’s portfolio. These and other vehicles could draw more investment in new therapies. Meeting the expected rise in demand for new and effective treatments may require new networks and partnerships. For example, large pharmaceutical companies working closely with small biotechs, charitable foundations, universities and CROs to develop new products. And governments may need to make these drugs available to patients for free to ensure the general use that can impart herd immunity.

    Such pragmatic approaches may be adopted as governments begin to see the societal costs and productivity impacts of other, less visible, but also widespread diseases such as Alzheimer’s.

    The need for speed
    Pharma is the most highly regulated industry in the world. But COVID-19 is raising questions about the impact on drug development of a conservative regulatory regime. The traditional priority of regulators was, “Do no harm.” The urgency of the present crisis is shifting that priority to “Test, treat, and prevent now.”

    Clearly, regulators are exercising greater pragmatism and are showing interest in sponsors better leveraging RWE and post-marketing surveillance to demonstrate safety. The suddenly evident fragility of global healthcare systems, as well as the lack of reliable real-world data on infectivity and even hospitalization rates, has made the need for more credible and actionable real-world information obvious and urgent. This is a huge opportunity for sponsors and healthcare systems to deliver what regulators and policymakers desperately need.

    Parexel is currently engaged in a considerable number of trials with RWE elements in the COVID-19 space.  For COVID-19 we are seeing RWE now being used early to identify treatments for further study and to accelerate drug development. RWE also presents an opportunity to leverage synthetic control arms particularly impactful for accelerating development of new treatments for oncology and rare diseases.

    Products for other conditions may follow this emerging model. Regulators recognize that data collected on drugs and treatments in traditionally randomized and controlled trial settings must be complemented by data from the real world. In other words, they appear to be moving from being risk-averse about RWE to prudently enthusiastic. This is an opportunity for the entire healthcare system to accelerate the speed of development without sacrificing safety, efficacy, or affordability – an unprecedented chance to innovate more quickly. A year from now, we will see if we have been able to leverage what we are learning for conditions other than COVID-19.

    An opportunity in a time of crisis
    The COVID-19 crisis is powerfully demonstrating the value of medicine and drug development –namely, how it keeps us safe and productive. People are becoming increasingly interested and invested in what the pharmaceutical industry does and how it does it, understanding that in both the long- and short-term, pharma is the industry that will ameliorate and end the economic dislocations and misery the virus has brought. Not only will the crisis change the way the public views the industry, but it will also change the way governments engage with it. As a society, we may come to accept that we need to provide incentives to ensure patient access to treatments unconstrained by cost. We cannot afford (and we never really could) to deny anyone timely access to treatment.

    Going forward, we in the industry will need to ask ourselves if we have been truly creative in responding to COVID-19. What new technologies have we embraced? How have we changed the ways we do business, develop drugs, and treat patients – not only for COVID-19 but for every condition? If nothing else, the COVID-19 pandemic has shown us that the entire healthcare ecosystem – from drug discovery to development to regulation to market access and health care – must become more efficient and useful to patients. The future has arrived early, and our healthcare paradigm must shift. If the various players in the pharmaceutical industry can collaborate to deliver products rapidly beyond the current emergency, then we will be far better prepared to withstand the next global outbreak, and whatever comes after that.

    Paul Bridges, Ph.D., Corporate Vice President, Worldwide Head of Regulatory & Access. Paul heads Parexel's Regulatory & Access organization worldwide and is currently based in Dublin Ireland. Prior to his current role, Paul headed the Americas Integrated Product Development (IPD). He earlier served as Vice President European Account Management for Parexel Consulting after a term as Senior Director of the consultancy’s regional UK IPD consulting team. Paul originally joined Parexel as a Principal Consultant providing strategic regulatory advice on all aspects of drug development with a special focus on Chemistry, Manufacturing and Controls (CMC).

     

    Sheela Hedge, Partner and Managing Director, Health Advances. Sheela is a leader in Health Advances’ biopharma practice, helping companies maximize the value of their assets and build winning market positions. Experienced in multiple therapeutic areas, she has particular expertise in metabolic and autoimmune diseases. Sheela brings a cross-sector lens to her biopharma clients, providing strategic advice on integrated solutions and convergent products. Sheela joined Health Advances in 2005 with a background in corporate strategy and health care provider operations.

    Related Searches
    • Clinical Trials
    • R&D
    • Drug Development
    • Information Technology
    Suggested For You
    Lonza Capsules and Health Ingredients Lonza Capsules and Health Ingredients
    Eurofins Viracor Biopharma Services Eurofins Viracor Biopharma Services
    MedPharm MedPharm
    Batavia Biosciences Batavia Biosciences
    PPD Achieves ISO Information Security Management Certification  PPD Achieves ISO Information Security Management Certification
    BioDuro, Sundia Partner as New CRDMO BioDuro, Sundia Partner as New CRDMO
    Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact Novavax, Par Sterile Products Enter COVID-19 Vax Mfg. Pact
    GRAM, J&J Enter COVID-19 Vax Manufacturing Pact GRAM, J&J Enter COVID-19 Vax Manufacturing Pact
    J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax
    Hovione to Support Manufacture of Remdesivir for COVID-19 Hovione to Support Manufacture of Remdesivir for COVID-19
    ARCA Submits IND for AB201 in COVID-19 ARCA Submits IND for AB201 in COVID-19
    BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production BioNTech to Acquire Novartis Mfg. Site for COVID-19 Vax Production
    Pharma Supply Chain Logistics & Potential COVID-19 Vaccines Pharma Supply Chain Logistics & Potential COVID-19 Vaccines
    Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies Lilly, Amgen Enter Antibody Mfg. Pact for COVID-19 Therapies
    FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine FDA Clears IND Application for Vaxart Oral COVID-19 Vaccine

    Related Expert's Opinion

    • Clinical Trials
      The Future of Clinical Trials Series: Part I

      The Future of Clinical Trials Series: Part I

      What will 2021 have in store for an industry in flux?
      Alison Holland, Head of Decentralized Trials, Medable, Maria Fotiu, Executive Director of Decentralized Solutions, Syneos Health 01.19.21

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21


    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21

    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20


    • Drug Development
      Navigating Uncertainty: Considerations for Life Sciences 2021

      Navigating Uncertainty: Considerations for Life Sciences 2021

      With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.
      Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP 12.11.20

    • Information Technology | Supply Chain
      The Pandemic & The Pharma Industry: 3 Things to Know

      The Pandemic & The Pharma Industry: 3 Things to Know

      The importance of vendor contract visibility, an increase in intense legal scrutiny, and new technology for greater agility and control.
      Colin Earl, CTO at Agiloft 11.16.20

    • Clinical Trials | Information Technology
      AI and Advanced Analytics

      AI and Advanced Analytics

      Equipped with the right tools, CROs are better positioned to develop optimal protocols, rapidly identify patients to enroll, and preempt study issues.
      Paul Oliver, Medidata 11.13.20


    • Clinical Trials | Information Technology
      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      eCOA: Addressing Barriers to Faster Deployment in Clinical Trials

      Clinical Outcome Assessments are an increasingly important tool in clinical research.
      Paul O'Donohoe, Scientific Lead, eCOA and Mobile Health, Medidata 11.13.20

    • Clinical Trials | Information Technology
      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Adding Remote Site Access to Sponsor Bids: What to Know as CRO

      Traditional monitoring has changed, CROs should build a portfolio of remote access solutions and have them ready.
      Ryan Jones, CEO, Florence Healthcare 10.13.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20


    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20

    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login